APP and fragile X syndrome: This suggests that targeting the synaptic deficits in FXS via an APP-focused approach may require pharmacotherapeutic manipulation of both amyloidogenic and non-amyloidogenic processing to restore homeostatic levels of APP metabolites (Westmark et al., 2011b, 2016a; Pasciuto et al., 2015).